Chronic Myeloproliferative Neoplasms

Cancer Cytogenetics

Volumn , Issue , 2010, Pages 209-232

  Vandenberghe, Peter ^a   Michaux, Lucienne ^a   Hagemeijer, Anne ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Chronic idiopathic myelofibrosis; Chronic myeloid leukemia; Myeloid neoplasm; Myeloproliferative disorders; Stem cell

Indexed keywords

EID: 77955508341     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118010136.ch8     Document Type: Chapter

References (126)

1. Aatola M, Armstrong E, Teerenhovi L, Borgstrom GH (1992): Clinical significance of the del(20q) chromosome in hematologic disorders. Cancer Genet Cytogenet 62:75-80.
2. Abe K, Kajii T, Niikawa N (1989): Disomic homozygosity in 21-trisomic cells: a mechanism responsible for transient myeloproliferative syndrome. Hum Genet 82:313-316.
3. Abe A, Emi N, Tanimoto M, Terasaki H, Marunouchi T, Saito H (1997): Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 90:4271-4277.
4. Al Assar O, Ul-Hassan A, Brown R, Wilson GA, Hammond DW, Reilly JT (2005): Gains on 9p are common genomic aberrations in idiopathic myelofibrosis: a comparative genomic hybridization study. Br J Haematol 129:66-71.
5. Andrieux J, Demory JL, Morel P, Plantier I, Dupriez B, Caulier MT, Bauters F, Lai JL (2002): Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia. Cancer Genet Cytogenet 137:68-71.
6. Andrieux J, Demory JL, Dupriez B, Quief S, Plantier I, Roumier C, Bauters F, Lai JL, Kerckaert JP (2004): Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer 39:82-87.
7. Andrieux J, Roche-Lestienne C, Geffroy S, Desterke C, Grardel N, Plantier I, Selleslag D, Demory JL, Lai JL, Leleu X, Bousse-Kerdiles C, Vandenberghe P (2007): Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis. Cancer Genet Cytogenet 178:11-16.
8. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH, Stockton DW, Semenza GL, Prchal JT (2002): Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32:614-621.
9. Bacher U, Haferlach T, Kern W, Hiddemann W, Schnittger S, Schoch C (2005): Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 84:250-257.
10. Bain BJ (2003): Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br] Haematol 122:173-179.
11. Baranger L, Baruchel A, Leverger G, Schaison G, Berger R (1990): Monosomy-7 in childhood hemopoietic disorders. Leukemia 4:345-349.
12. Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L, Cervera J, Moscardo F, Sanz MA, Cross NC (2002): The t(4;22)(qI2;ql 1) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 11:1391-1397.
13. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005): Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061.
14. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, Delhommeau F, Casadevall N, Vainchenker W, Thomas G, Najman A (2006): Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108: 346-352.
15. Belloni E, Trubia M, Gasparini P, Micucci C, Tapinassi C, Confalonieri S, Nuciforo P, Martino B, Lo-Coco F, Pelicci PG, Di Fiore PP (2005): 8pl 1 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFRl and TIF1 genes. Genes Chromosomes Cancer 42:320-325.
16. Bench AJ, Pahl HL (2005): Chromosomal abnormalities and molecular markers in myeloproliferative disorders. Semin Hematol 42:196-205.
17. Bench AJ, Nacheva EP, Champion KM, Green AR (1998): Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol 11:819-848.
18. Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, Champion KM, Li J, Whittaker P, Stavrides G, Hunt AR, Huntly BJ, Campbell LJ, Bentley DR, Deloukas P, Green AR (2000): Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 19:3902-3913.
19. Berger R, Bernheim A, Le Coniat M, Vecchione D, Flandrin G, Dresch C, Najean Y (1984): Chromosome studies in polycythemia vera patients. Cancer Genet Cytogenet 12:217-223.
20. Bohm J, Kock S, Schaefer HE, Fisch P (2003): Evidence of clonality in chronic neutrophilic leukaemia. / Clin Pathol 56:292-295.
21. Busson M, Romana S, Nguyen Khac F, Bernard O, Berger R (2004): Cryptic translocations involving chromosome 20 in polycythemia vera. Ann Genet 47:365-371.
22. Campbell LJ, Garson OM (1994): The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 8:67-71.
23. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Bousse-Kerdiles MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Briere J, Harrison CN, Green AR, Reilly JT (2006): V6i 7F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107:2098-2100.
24. Carpenter E, Valverde-Garduno V, Sternberg A, Mitchell C, Roberts I, Vyas P, Vora A (2005): GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol 128:548-551.
25. Chen Z, Notohamiprodjo M, Guan XY, Paietta E, Blackwell S, Stout K, Turner A, Richkind K, Trent JM, Lamb A, Sandberg AA (1998): Gain of 9p in the pathogenesis of polycythemia vera. Genes Chromosomes Cancer 22:321-324.
26. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003): A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N EnglJ Med 348:1201-1214.
27. Cross NC, Reiter A (2002): Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16:1207-1212.
28. Curtis CE, Grand FH, Musto P, Clark A, Murphy J, Perla G, Minervini MM, Stewart J, Reiter A, Cross NC (2007): Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 138:77-81.
29. Daghistani D, Toledano SR, Curless R (1990): Monosomy 7 syndrome. Clinical heterogeneity in children and adolescents. Cancer Genet Cytogenet 44:263-269.
30. Demory JL, Dupriez B, Fenaux P, Lai JL, Beuscart R, Jouet JP, Deminatti M, Bauters F (1988): Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 72:855-859.
31. Diez-Martin JL, Graham DL, Petitt RM, Dewald GW (1991): Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 66:287-299.
32. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, Tsuboi K, Nitta M, Miyazaki H, Iida S, Ueda R (2004): Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103:4198^200.
33. Dingli D, Grand FH, Mahaffey V, Spurbeck J, Ross FM, Watmore AE, Reilly JT, Cross NC, Dewald GW, Tefferi A (2005): Der(6)t(l;6)(q21-23;p21.3): aspecific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. Br J Haematol 130:229-232.
34. Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A (2006): Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 106:1985-1989.
35. Djordjevic V, Dencic-Fekete M, Jovanovic J, Bizic S, Jankovic G, Bogdanovic A, Cemerikic-Martinovic V, Gotic M (2007): Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients. Cancer Genet Cytogenet 173:57-62.
36. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F (1996): Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88:1013-1018.
37. Faed MJ, Robertson J, Todd AS, Sivakumaran M, Tarnow-Mordi WO (1990): Trisomy 21 in transient myeloproliferative disorder. Cancer Genet Cytogenet 48:259-264.
38. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S (1981): Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 58:916-919.
39. Fioretos T, Panagopoulos I, Lassen C, Swedin A, Billstrom R, Isaksson M, Strombeck B, Olofsson T, Mitelman F, Johansson B (2001): Fusion of the BCR and the (ibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(pl 1;q 11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer 32:302-310.
40. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A (2006): KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108:2366-2372.
41. Golub TR, Barker GF, Lovett M, Gilliland DG (1994): Fusion of PDGF receptor beta to a novel ets-like gene, tej, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307-316.
42. Gotlib J (2005): Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol 114:7-25.
43. Grand EK, Grand FH, Chase AJ, Ross FM, Corcoran MM, Oscier DG, Cross NC (2004a): Identification of a novel gene, FGFRJOP2, fused to FGFR1 in 8p 11 myeloproliferative syndrome. Genes Chromosomes Cancer 40:78-83.
44. Grand FH, Burgstaller S, Kuhr T, Baxter EJ, Webersinke G, Thaler J, Chase AJ, Cross NC (2004b): p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5; 15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 64:7216-7219.
45. Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, Wormann B, Haase D, Bohlander SK (2005): A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q 11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 44:329-333.
46. Groupe Franijais de Cytogenetique Hematologique (1988): Cytogenetics of acutely transformed chronic myeloproliferative syndromes without a Philadelphia chromosome. A multicenter study of 55 patients. Cancer Genet Cytogenet 32:157-168.
47. Guasch G, Mack GJ, Popovici C, Dastugue N, Birnbaum D, Rattner JB, Pebusque MJ (2000): FGFR1 is fused to the centrosome-associated protein CEP110 in the 8pl2 stem cell myeloproliferative disorder with t(8;9)(pl2;q33). Blood 95:1788-1796.
48. Guasch G, Popovici C, Mugneret F, Chaffanet M, Pontarotti P, Birnbaum D, Pebusque MJ (2003): Endogenous retro viral sequence is fused to FGFR1 kinase in the 8pl 2 stem-cell myeloproliferative disorder with t(8;19)(pl2;ql3.3). Blood 101:286-288.
49. Guasch G, Delaval B, Arnoulet C, Xie MJ, Xerri L, Sainty D, Birnbaum D, Pebusque MJ (2004): FOP- FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice. Blood 103:309-312.
50. Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B, Kiladjian JJ, Varkonyi J, Antunovic P, Westwood NB, Arno MJ, Mohamedali A, Gaken J, Kontou T, Czepulkowski BH, Twine NA, Tamaska J, Csomer J, Benedek S, Gattermann N, Zipperer E, Giagounidis A, Garcia-Casado Z, Sanz G, Mufti GJ (2006): The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 20:1319-1321.
51. Jacobson RJ, Salo A, Fialkow PJ (1978): Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51:189-194.
52. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005): A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148.
53. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehhnann R, Cross NC, Reiter A, Grimwade D (2007): Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1 -PDGFRA-positive chronic eosinophilic leukemia. Blood 109:4635-^640.
54. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB (2003): Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101:4660-4666.
55. Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT (1997): Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 90:2057-2061.
56. Kralovics R, Guan Y, Prchal JT (2002): Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 30:229-236.
57. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005): A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790.
58. La Starza R, Wlodarska I, Aventin A, Falzetti D, Crescenzi B, Martelli MF, Van den Berghe H, Mecucci C (1998): Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies. Blood 91:231-237.
59. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL (2006): JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108:1652-1660.
60. Lahortiga I, Akin C, Cools J, Wilson TM, Mentens N, Arthur DC, Marie I, Noel P, Kocabas C, Marynen P, Lessin LS, Wlodarska I, Robyn J, Metcalfe DD (2008): Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 93:49-56.
61. Lawler SD (1980): Cytogenetic studies in Philadelphia chromosome-negative myeloproliferative disorders, particularly polycythaemia rubra vera. Clin Haematol 9:159-174.
62. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW (2005a): The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106:3377-3379.
63. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S. Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005b): Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397.
64. Levine RL, Wadleigh M, Sternberg DW, Wlodarska I, Galinsky I, Stone RM, DeAngelo DJ, Gilliland DG, Cools J (2005c): K1AA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5; 14)(q33;q32). Leukemia 19:27-30.
65. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I (1996): Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12:312-314.
66. Luna-Fineman S, Shannon KM, Atwater SK, Davis J, Masterson M, Ortega J, Sanders J, Steinherz P, Weinberg V, Lange BJ (1999): Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood 93:459-466.
67. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ (2002): The c-KIT mutation causing human mastocytosis is resistant to STI571 and dther KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741-1744.
68. Macdonald D, Reiter A, Cross NC (2002): The 8pl I myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 107:101-107.
69. MacGrogan D, Alvarez S, DeBlasio T, Jhanwar SC, Nimer SD (2001): Identification of candidate genes on chromosome band 20ql2 by physical mapping of translocation breakpoints found in myeloid leukemia cell lines. Oncogene 20:4150-4160.
70. Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ, Dunbar CE (2001): Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 98:2518-2525.
71. Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F (1991): Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature. Leukemia 5:214-220.
72. Morerio C, Acquila M, Rosanda C, Rapella A, Dufour C, Locatelli F, Maserati E, Pasquali F, Panarello C (2004): HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;pl 1.2). Cancer Res 64:2649-2651.
73. Nacheva E, Holloway T, Carter N, Grace C, White N, Green AR (1995): Characterization of 20q deletions in patients with myeloproliferative disorders or myelodysplastic syndromes. Cancer Genet Cytogenet 80:87-94.
74. Najfeld V, Montella L, Scalise A, Fruchtman S (2002): Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 119:558-566.
75. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A (2003a): CHIC2 deletion, a surrogate for FIPIL1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102:3093-3096.
76. Pardanani AD, Morice WG, Hoyer JD, Tefferi A (2003b): Chronic basophilic leukemia: a distinct clinico-pathologic entity? Eur J Haematol 71:18-22
77. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A (2006): MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108:3472-3476.
78. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soil R, Gilliland DG, Tefferi A (2007a): TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21:1658-1668.
79. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A (2007b): Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 21:1960-1963.
80. Pastore C, Nomdedeu J, Volpe G, Guerrasio A, Rege-Cambrin G, Parvis G, Pautasso M, Daglio C, Mazza U, Saglio G (1995): Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. Genes Chromosomes Cancer 14:106-111.
81. Pastore YD, Jelinek J, Ang S, Guan Y, Liu E, Jedlickova K, Krishnamurti L, Prchal JT (2003): Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 101:1591-1595.
82. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P (1997): Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9; 12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90:2535-2540.
83. Popovici C, Zhang B, Gregoire MJ, Jonveaux P, Lafage-Pochitaloff M, Bimbaum D, Pebusque MJ (1999): The t(6;8)(q27;p 11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 93A3SI-US9.
84. Raskind WH, Jacobson R, Murphy S, Adamson JW, Fialkow PJ (1985): Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. J Clin Invest 75:1388-1390.
85. Rege-Cambrin G, Mecucci C, Tricot G, Michaux JL, Louwagie A, Van Hove W, Francart H, Van den Berghe H (1987): A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 25:233-245.
86. Rege-Cambrin G, Speleman F, Kerim S, Scaravaglio P, Carozzi F, Dal Cin P, Michaux JL, Offner F, Saglio G, Van den Berghe H (1991): Extra translocation + der(lq9p) is a prognostic indicator in myeloproliferative disorders. Leukemia 5:1059-1063.
87. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, Potter A (1997): Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 98:96-102.
88. Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, Aguiar RC, Goncalves C, Hernandez JM, Jennings BA, Goldman JM, Cross NC (1998): Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(pl I;ql2) myeloproliferative syndrome. Blood 92:1735-1742.
89. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC (2005): The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65:2662-2667.
90. Roche-Lestienne C, Andrieux J (2007): Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera. Pathol Biol 55:49-55.
91. Rosati R, La Starza R, Bardi A, Luciano L, Matteucci C, Pierini V (2006a): PDGFRB fuses to TPM3 in the t(l;5)(q23;q33) of chronic eosinophilic leukemia and to NDE1 in the t(5;16)(q33;pl3) of chronic myelomonocytic leukemia. Haematologica 91(Suppl 1): 214.
92. Rosati R, La Starza R, Luciano L, Gorello P, Matteucci C, Pierini V, Romoli S, Crescenzi B, Rotoli B, Martelli MF, Pane F, Mecucci C (2006b): TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia. Leukemia 20:1623-1624.
93. Ross TS, Bernard OA, Berger R, Gilliland DG (1998): Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;ql 1.2). Blood 91:4419-4426.
94. Roulston D, Espinosa R III, Stoffel M, Bell GI, Le Beau MM (1993): Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood 82:3424-3429.
95. Schwaller J, Anastasiadou E, Cain D, Kutok J, Wojiski S, Williams IR, La Starza R, Crescenzi B, Sternberg DW, Andreasson P, Schiavo R, Siena S, Mecucci C, Gilliland DG (2001): H4(DIOS17O), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 97:3910-3918.
96. Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, Cross NC (2006): Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 20:827-832.
97. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR (2007): JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459-468.
98. Sessarego M, Defferrari R, Dejana AM, Rebuttato AM, Fugazza G, Salvidio E, Ajmar F (1989): Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. Cancer Genet Cytogenet 43:57-65.
99. Shannon KM, Turhan AG, Rogers PC, Kan YW (1992): Evidence implicating heterozygous deletion of chromosome 7 in the pathogenesis of familial leukemia associated with monosomy 7. Genomics 14:121-125.
100. Sinclair EJ, Forrest EC, Reilly JT, Watmore AE, Potter AM (2001): Fluorescence in situ hybridization analysis of 25 cases of idiopathic myelofibrosis and two cases of secondary myelofibrosis: monoallelic loss of RBI, D13S319 and D13S25 loci associated with cytogenetic deletion and translocation involving 13ql4. Br J Haematol 113:365-368.
101. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A (2005): The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207-1209.
102. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Watte! E, Bordessoule D, Bauters F, Fenaux P (1998): Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with I7p deletion. Blood 91:616-622.
103. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, Williams IR, Gilliland DG, Cools J (2006): Activation of FIP1L1 -PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIPlLl-independent. Proc NatlAcadSci USA 103:8078-8083.
104. Swolin B, Weinfeld A, Westin J (1986): Trisomy lq in polycythemia vera and its relation to disease transition. Am J Hematol 22:155-167.
105. Swolin B, Weinfeld A, Westin J (1988): A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 72:386-395.
106. Swolin B, Rodjer S, Roupe G (2000): Cytogenetic studies in patients with mastocytosis. Cancer Genet Cytogenel 120:131-135.
107. Swolin B, Rodjer S, Ogard I, Roupe G (2002): Trisomies 8 and 9 not detected with FISH in patients with mastocytosis. Am J Hematol 70:324-325.
108. Tefferi A, Gilliland DG (2007): Oncogenes in myeloproliferative disorders. Cell Cycle 6:550-566.
109. Tefferi A, Vardiman JW (2008): Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14-22.
110. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW (2001): Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 113:763-771.
111. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foa R, Larocca LM (2007): Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 25:1048-1053.
112. Third International Workshop on Chromosomes in Leukemia (1981): Report on essential thrombocythemia. Cancer Genet Cytogenet 4:138-142.
113. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dimhofer S, Schwaller J, Skoda RC (2008): Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice. Blood 111:3931-3940.
114. Tothova E, Fricova M, Stecova N, Hlebaskova ML Kafkova A, Raffac S, Guman T, Svorcova E, Nebesnakova E (2001): Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17. Neoplasma 48:389-392.
115. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P (2004): Clinical and molecular features of FIP1L1 -PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18:734-742.
116. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De SV, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T (2007): Clinical profile of homozygous JAK2 617V >F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840-846.
117. Vardiman JW, Harris NL, Brunning RD (2002): The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302.
118. Vizmanos JL, Novo FJ, Roman JP, Baxter EJ, Lahortiga I, Larrayoz MJ, Odero MD, Giraldo P, Calasanz MJ, Cross NC (2004): NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res 64:2673-2676.
119. Walz C, Chase A, Schoch C, Weisser A, Schlegel F, Hochhaus A, Fuchs R, Schmitt-Graff A, Hehlmann R, Cross NC, Reiter A (2005): The t(8; 17)(p 11;q23) in the 8p 11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia 19:1005-1009.
120. Walz C, Curtis C, Schnittger S, Schultheis B, Metzgeroth G, Schoch C, Lengfelder E, Erben P, Muller MC, Haferlach T, Hochhaus A, Hehlmann R, Cross NC, Reiter A (2006): Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;ql2q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 45:950-956.
121. Walz C, Metzgeroth G, Haferlach C, Schmitt-Graeff A, Fabarius A, Hagen V, Prummer O, Rauh S, Hehlmann R, Hochhaus A, Cross NC, Reiter A (2007): Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 92:163-169.
122. Wang JC, Lang HD, Lichter S, Weinstein M, Benn P (1992): Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br J Haematol 80:184-188.
123. Wilkinson K, Velloso ER, Lopes LF, Lee C, Aster JC, Shipp MA, Aguiar RC (2003): Cloning of the t (I;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 102:4187-4190.
124. Xu G, Kanezaki R, Toki T, Watanabe S, Takahashi Y, Terui K, Kitabayashi I, Ito E (2006): Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome. Leukemia 20:1002-1008.
125. Zaccaria A, Tura S (1978): A chromosomal abnormality in primary thrombocythemia. N EnglJ Med 298:1422-1423.
126. Zipursky A (2003): Transient leukaemia: a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 120:930-938.